VANCOUVER, BC, June 29,
2023 /PRNewswire/ - Numinus Wellness
Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF),
a mental health care company advancing innovative treatments and
safe, evidence-based psychedelic-assisted therapies, will release
its financial results for the quarter ended May 31, 2023, after market close on Monday, July 17, 2023.
Interested parties are invited to participate in the Company's
Q3 2023 results conference call and webcast occurring on the same
day, at 5:30 p.m. Eastern time /
2:30 p.m. Pacific time. During the
call, Numinus executives will review the Company's performance and
recent initiatives, and answer questions from analysts.
To listen to the live webcast, please register at:
https://events.q4inc.com/attendee/612414870
The webcast will also be archived on the Events and
Presentations page of Numinus' Investor Relations website:
https://www.investors.numinus.com/events-and-presentations
To participate in the live conference call, please use the
following dial-in information:
- 1 (888) 330-3632 (Toll-free North
America)
- 1 (646) 960-0837 (International)
- Please ask to participate in Numinus' Q3 2023 Results
Call.
To avoid any delays in joining the call, please dial in at least
five minutes prior to the call start time. If prompted, please
provide conference passcode 3547386.
A replay of the conference call can also be accessed after
8:30 p.m. Eastern time / 5:30 p.m. Pacific time on July 17, 2023, at 1-800-770-2030 or
1-647-362-9199 (using passcode 3547386). The replay will be
available until July 31, 2023.
About Numinus
Numinus Wellness (TSX: NUMI) helps
people to heal and be well through the development and delivery of
innovative mental health care and access to safe, evidence-based
psychedelic-assisted therapies. The Numinus model - including
psychedelic production, research and clinic care - is at the
forefront of a transformation aimed at healing rather than managing
symptoms for depression, anxiety, trauma, pain and substance use.
At Numinus, we are leading the integration of psychedelic-assisted
therapies into mainstream clinical practice and building the
foundation for a healthier society.
Learn more at www.numinus.com and follow us
on LinkedIn, Facebook, Twitter,
and Instagram.
Forward-looking statements
Statements and other
information contained in this press release about anticipated
future events constitute forward-looking statements.
Forward-looking statements are often, but not always, identified by
the use of words such as "seek", "anticipate", "believe", "plan",
"estimate", "expect" and "intend" and statements that an event
"may", "will", "should", "could" or "might" occur or other similar
expressions. Forward-looking statements are subject to risks and
uncertainties and other factors that could cause actual results to
differ materially from those contained in the forward-looking
statements. Forward-looking statements are based on estimates and
opinions of management at the date the statements are made. There
is no assurance that Health Canada will approve the application.
The Company does not undertake any obligation to update
forward-looking statements even if circumstances or management's
estimates or opinions should change except as required by
applicable laws. Investors should not place undue reliance on
forward-looking statements.
View original
content:https://www.prnewswire.com/news-releases/numinus-to-host-q3-2023-results-conference-call-on-july-17-2023-301866477.html
SOURCE Numinus Wellness Inc.